MDxHealth SA - ADR

Name: MDxHealth SA - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: MDxHealth SA - ADR

Stock Card

$0.71

$-0.01 (-1.44%)

As on 02-Sep-2026 13:37EDT

Market cap

$69 Mln

Revenue (TTM)

$163 Mln

P/E Ratio

P/B Ratio

23.6

Div. Yield

0 %

MDxHealth SA - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.71 High: 0.75

52 Week Range

Low: 0.40 High: 5.33

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-24.4 %
ROCE

-- %
Industry P/E

33.81
EV/EBITDA

17.6
Debt to Equity

-7.9
Book Value

$--
EPS

$-1.1
Face value

--
Shares outstanding

95,417,382

10 Years Aggregate

CFO

$-211.74 Mln

EBITDA

$-219.96 Mln

Net Profit

$-284.91 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
MDxHealth SA - ADR	-80.1	69.8	7.5	-80.0	-72.0	--	--
BSE Sensex	-9.6	-2.0	3.1	-4.7	5.4	6.0	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
MDxHealth SA - ADR	50.6	-39.6	-94.0
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
MDxHealth SA - ADR	0.7	68.8	163.4	-52.9	-16.3	--	--	23.6
Chemed Corp (CHE)	525.4	7,065.2	2,595.0	275.0	14.1	30.4	26.9	8.4
Encompass Health Corp (EHC)	120.8	11,869.0	6,206.1	621.0	18.6	16.2	20.2	4.6
Hims Hers Health Inc (HIMS)	29.1	7,433.4	2,578.1	-142.0	-6.3	-32.8	--	22.4
Lifestance Health Group Inc (LFST)	12.9	4,703.1	1,584.8	50.6	4.9	3.4	94.7	3.2
National HealthCare (NHC)	220.7	3,707.8	1,559.0	140.3	12.1	12.6	26.3	3.3
Option Care Health (OPCH)	24.0	3,579.9	5,693.5	209.6	6.0	16.2	18.1	2.8
RadNet (RDNT)	76.2	5,871.6	2,268.9	-21.1	4.7	-4.5	--	5.4
Sotera Health Co (SHC)	18.9	5,499.2	1,216.2	163.5	33.5	25.7	33.8	8.4
The Ensign Group (ENSG)	172.3	10,081.7	5,486.7	378.7	9.2	16.2	27.1	4.1

Shareholding Pattern

View Details

About MDxHealth SA - ADR

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates... epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. Read more

CEO & Executive Director

Mr. Michael K. McGarrity
CEO & Executive Director

Mr. Michael K. McGarrity
Headquarters

Herstal
Website

https://mdxhealth.com

FAQs for MDxHealth SA - ADR

What is the current share price of MDxHealth SA - ADR Today?

The share price of MDxHealth SA - ADR is $0.71 (NASDAQ) as of 02-Sep-2026 13:37 EDT. MDxHealth SA - ADR has given a return of -72.02% in the last 3 years.

What is the current PB & PE ratio of MDxHealth SA - ADR?

Since, TTM earnings of MDxHealth SA - ADR is negative, P/E ratio is not available.
The P/B ratio of MDxHealth SA - ADR is 23.64 times as on 28-Aug-2026, a 568 premium to its peers’ median range of 3.54 times.

PE & PB ratio at the end of financial year.